Abstract
Background and Aims: My Diabetes My Way (MDMW) is Scotland’s interactive website and mobile app for people with diabetes and carers (currently ~55,000 registrants). It contains multimedia resources for diabetes education and offers access to electronic personal health records. This study aims to assess the cost- utility of MDMW compared to routine diabetes care in people with type 2 diabetes who do not use insulin.
Methods: Analysis used the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model 2. Clinical parameters of MDMW users (n = 2,576) were compared with a matched cohort of individuals receiving routine care alone (n = 11,628). Matching criteria: age, diabetes duration, sex and socio- economic status. Impact on life expectancy, quality- adjusted life years (QALY) and costs of treatment and complications were simulated over ten years, alongside a 10% sensitivity analysis.
Results: MDMW cohort: 1670 (64.8%) men; average age 64.3 years; duration of diabetes 5.5 years. Females: average age 61.6; duration 4.7 years. The cumulative mean QALY (95% CI) gain: 0.054 (0.044; 0.062) years. Mean difference in cost: - £118.72 (- £150.16; - £54.16) over ten years. Increasing MDMW costs (10%): - £50.49 (- £82.24; £14.14). Decreasing MDMW costs (10%): - £186.95 (- £218.53; - £122.51).
Conclusions: MDMW is ‘dominant’ over usual care (cost- saving and life improving) in supporting self- management in people with type 2 diabetes not treated with insulin. Wider use may result in significant cost savings through delay or reduction of long- term complications and increased life expectancy in Scotland and other countries. MDMW may be among the most cost- effective interventions currently avail-able to support diabetes.
Methods: Analysis used the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model 2. Clinical parameters of MDMW users (n = 2,576) were compared with a matched cohort of individuals receiving routine care alone (n = 11,628). Matching criteria: age, diabetes duration, sex and socio- economic status. Impact on life expectancy, quality- adjusted life years (QALY) and costs of treatment and complications were simulated over ten years, alongside a 10% sensitivity analysis.
Results: MDMW cohort: 1670 (64.8%) men; average age 64.3 years; duration of diabetes 5.5 years. Females: average age 61.6; duration 4.7 years. The cumulative mean QALY (95% CI) gain: 0.054 (0.044; 0.062) years. Mean difference in cost: - £118.72 (- £150.16; - £54.16) over ten years. Increasing MDMW costs (10%): - £50.49 (- £82.24; £14.14). Decreasing MDMW costs (10%): - £186.95 (- £218.53; - £122.51).
Conclusions: MDMW is ‘dominant’ over usual care (cost- saving and life improving) in supporting self- management in people with type 2 diabetes not treated with insulin. Wider use may result in significant cost savings through delay or reduction of long- term complications and increased life expectancy in Scotland and other countries. MDMW may be among the most cost- effective interventions currently avail-able to support diabetes.
| Original language | English |
|---|---|
| Article number | P151 |
| Pages (from-to) | 55 |
| Number of pages | 1 |
| Journal | Diabetic Medicine |
| Volume | 38 |
| Issue number | S1 |
| Publication status | Published - 1 Apr 2021 |
| Event | Diabetes UK Professional Conference 2021 - Online Duration: 19 Apr 2021 → 30 Apr 2021 |
